INTRODUCTION
Lipopolysaccharide (LPS) or endotoxin is a molecule that comprises the outer membrane of Gram-negative bacteria. LPS provides a highly potent stimulus for cells of the immune system and this action constitutes an integral part of the host systemic inflammatory response. LPS induced cellular activation is mediated through two host proteins; LPS binding protein (LBP) and the leukocyte receptor CD14. LBP was discovered as a 60 kDa acute phase serum glycoprotein which binds LPS 1,2 and subsequently delivers LPS to other molecules. 3, 4 LPS and LBP activate macrophages and neutrophils through a 55 kDa glycosylphosphatidylinositol (GPI) anchored cell surface receptor known as membrane CD14 (mCD14). 5 A soluble form of the CD14 protein also normally exists in serum (sCD14).
In addition to their well established roles as proinflammatory effector molecules, LBP and mCD14 also act in the cellular clearance of endotoxin. In this latter role, LBP is an opsonin for whole Gram-negative bacteria 6 and mCD14 is a receptor for both bacteria opsonized with LBP 7, 8 and for LBP-LPS complexes. 9 Binding of these particles leads to cellular internalization followed by degradation and inactivation of LPS. 10 Thus, internalization of LPS leads to a potential dampening of the host immune response. CD14 mediated internalization of LPS appears to proceed via a constitutive macropinocytic pathway independent of coated pits or caveolae 11 At least four independent lines of evidence suggest that bulk binding and clearance of LPS is a separate event from that leading to cellular activation. 9, [11] [12] [13] Lipopolysaccharide (LPS) binding protein (LBP) is a serum molecule that mediates cellular activation in response to endotoxin by ensuring the delivery of LPS to either soluble or membrane bound forms of CD14. Aside from this activating role, previous work has shown that LBP and LPS can bind to cells by forming large aggregates which are anchored by mCD14. This binding phenomenon does not correlate with cellular activation. To further characterize these events, we have generated a biologically active radiolabeled LBP ligand with high specific activity. Through the use of this ligand in whole cell binding assays, we have confirmed that the binding of LBP to CHO cells expressing mCD14 is LPS dependent, blocked by the anti-LBP antibodies 18G4 and 2B5, and appears to involve the self aggregation of LBP-LPS complexes on the cell surface. Moreover, we discovered that non-transfected CHO cells also exhibit a binding phenomenon with all the above characteristics of CHO-mCD14 cells. Binding through this latter receptor(s) is distinct from that mediated by mCD14 in that it is not inhibited by anti-CD14 antibodies 28C5 or 18E12. In addition, unlike binding to mCD14, binding of LBP-LPS complexes to this novel receptor is abolished by pretreatment of cells with trypsin. Using proteinase K we found that LBP-LPS complexes bound either by mCD14 or this new receptor are subsequently internalized. Pretreatment of cells with trypsin also abolishes their ability to internalize mCD14 bound LBP-LPS complexes. The novel receptor for LBP-LPS complexes has been detected on many cell types and may be a receptor required for the cellular clearance of LPS.
Previous work has examined the binding of biosynthetically labeled LBP to mCD14. 9 As expected, binding of LBP to mCD14 is LPS dependent and maximal binding is observed when the molar ratio of LBP to LPS is about 1:2. Moreover, the binding of LBP to mCD14 does not saturate as long as sufficient LPS is supplied, that is, as long as the molar ratio of LPS to LBP is kept constant. 9 This is probably due to the ability of LBP-LPS complexes to self aggregate, a phenomenon which has been observed in solution with equal molar amounts of LBP and LPS. 4 Once bound, LBP-LPS complexes are internalized. None of these events lead to cellular activation as certain anti-LBP antibodies that abrogate the binding of LBP-LPS complexes to CD14 have no measurable effect on cellular stimulation. 9 Recently, we described the binding of radiolabeled sCD14 to non-CD14 expressing cells. 14 Cell surface binding of sCD14 requires both LBP and LPS. The LBP in these experiments is not acting to deliver LPS to CD14. In fact, ternary sCD14-LBP-LPS complexes were found to bind to the cells. Binding of ternary sCD14-LBP-LPS complexes to non-CD14 bearing cells has many similar characteristics to that of the binding of LBP-LPS to mCD14 including nonsaturability as well as inhibition by certain anti-LBP antibodies. Since these experiments measure binding using labeled sCD14, we do not know the sCD14 dependence of this binding. In fact, it is possible that sCD14 is not required for the binding but is carried along with LBP-LPS aggregates as they bind a cell surface component. 14 This possibility was difficult to rule out using excess cold components, since the binding of ternary sCD14-LBP-LPS complexes does not saturate.
RESULTS AND DISCUSSION
The aim of our studies was to address the sCD14 dependency of the aforementioned binding and determine whether non-CD14 expressing cells bear a novel receptor for LBP-LPS complexes. To this end, we generated a full length LBP cDNA construct encoding a radiolabelable protein kinase A site followed by a six histidine affinity tag at the carboxyl terminus. This protein, hereafter called LBPAH, was expressed in a baculovirus system and purified to over 95% homogeneity by Ni-NTA affinity chromatography. Purified LBPAH was radiolabeled to high specific activity using protein kinase A and [γ-33 P]-ATP. Upon removal of the excess ATP by microdialysis, we found the protein to possess a high specific activity (1000 Ci/mmole). Labeled LBPAH retains the ability to bind LPS and transfer LPS to sCD14. Moreover, radiolabeled LBPAH retains biological activity as it mediates LPS induced IL-8 production of CD14 expressing myeloid cells.
Radiolabeled LBPAH was utilized in whole cell binding assays using CHO cells expressing CD14, as this was the cell type initially used to characterize the binding of LBP to CD14. As expected, binding of LBP to CHO cells expressing CD14 (CHO-CD14) was LPS dependent and maximal when the molar ratio of LBP to LPS was approximately 1:3. Cellular binding was only observed when the LBP was pre-incubated with the LPS at 37°C, suggesting a requirement for the formation of LBP-LPS complexes (Fig. 1 ). Cell surface binding of LBP-LPS complexes was observed at 4°C, conditions which prevent cellular internalization. Surprisingly, we observed that CHO cells transfected with empty vector alone (CHO-RSV), which do not express CD14, were capable of binding LBP-LPS complexes at levels comparable to that observed using CHO-CD14 cells. These results suggest that CHO cells endogenously express a receptor for LBP-LPS complexes. The binding to both CHO-RSV and CHO-CD14 cells was inhibited by a 100-fold molar excess of LBP. However, the addition of LPS with the excess LBP, so that the molar ratio of LBP to LPS was kept at 1:3, did not inhibit the binding (Fig.  1 ). This finding predicts that, if sufficient LPS is present, the binding of LBP-LPS complexes will not saturate. This result was confirmed as the binding of LBP-LPS complexes did not saturate when measured over 4 logs of LBP-LPS concentration.
To determine if the putative CHO cell receptor for LBP-LPS complexes is a protein component, we pretreated the Cell surface binding of LBP-LPS complexes 53 cells with proteinase K, washed them thoroughly, and tested the cells for their ability to bind LBP-LPS complexes. Pretreatment of the cells abolished the binding suggesting that the receptor for the LBP-LPS complexes is indeed a protein. To extend this observation, we also pretreated cells with the protease trypsin. Trypsin pretreatment completely abrogated the binding of LBP-LPS complexes to CHO-RSV cells but had no effect on the binding of these complexes to CHO-CD14 cells (Fig. 2) . These results suggest the presence of a novel receptor for LBP-LPS complexes which, unlike mCD14, is trypsin sensitive. The resistance of CD14 to trypsin is supported by a report showing that mCD14 retains the ability to bind LPS and has an unaltered SDS-PAGE and Western blot profile even after trypsin treatment of peritoneal macrophages. 15 A panel of anti-LBP and anti-CD14 antibodies were tested for their effects on the binding of LBP-LPS complexes to whole cells. Binding to all cell types was completely inhibited by the addition of the anti-LBP antibodies 1E8, 18G4 and 2B5 (Fig. 3) . IE8 and 18G4 have no effect on LPS and LBP mediated cellular activation 9 suggesting that these binding events do not directly lead to cellular activation. The anti-CD14 antibodies, 28C5 and 18E12, had no effect on the binding of LBP-LPS complexes to CHO-RSV or CHO-CD14 cells but greatly inhibited the binding of these complexes to trypsin treated CHO-CD14 cells (Fig. 3) . Thus, trypsin pretreatment of the cells reveals the CD14 dependent binding of LBP-LPS complexes confirming that the endogenous receptor for these complexes is trypsin sensitive while mCD14 is not.
To ascertain whether binding of the LBP-LPS complexes leads to cellular internalization, we performed experiments in which the binding was allowed to proceed on ice for 90 min after which the cells were shifted to 37°C for various times and placed back on ice. Internalized complexes were measured by stripping the cell surface complexes using proteinase K. Both CHO-RSV and CHO-CD14 cells exhibited a comparable time dependent increase in cell associated counts at 37°C indicating that labeled LBP was being internalized by the cells. As expected, trypsin pretreated CHO-RSV cells did not bind or internalize LBP-LPS complexes. Surprisingly, trypsin pretreated CHO-CD14 cells were dramatically inefficient at internalizing LBP even though the mCD14 on the surface of these cells bound Fig. 2 . Trypsin treatment abolishes non-mCD14 mediated cellular binding of LBP-LPS complexes. CHO cells were removed from plates using EDTA and cells were resuspended in either PBS or Trypsin-EDTA for 10 min at room temperature. The cells were washed 3 times in binding buffer prior to addition to binding reactions. The binding reactions contained 1 nM labeled LBP which had been pre-incubated at 37°C in either the presence or absence of a 3-fold molar excess of Re595 LPS. The binding reactions were incubated for 1 h on ice prior to processing as described in the caption to Figure 1 . the LBP-LPS complexes. These latter results were confirmed using cold LBP and biosynthetically radiolabeled LPS and suggest that the putative receptor may co-operate with mCD14 in ensuring the internalization and clearance of LBP-LPS complexes.
CONCLUSIONS
In conclusion, we have begun to characterize a novel cellular receptor for LBP-LPS complexes. Cellular binding of LBP to either this novel receptor or mCD14 is LPS dependent, nonsaturable when the molar ratio of LBP to LPS is kept constant, and blocked by anti-LBP antibodies. The nonsaturability of the binding probably results from the self aggregation of LBP-LPS complexes on the receptor, a phenomenon observed in solution. 4 Thus, mCD14 does not possess a specific ability to bind multiple numbers of LBP-LPS complexes. Binding of LBP-LPS complexes to this novel receptor is distinct from binding to mCD14 in that it is unaffected by anti-CD14 antibodies and is trypsin sensitive. In this regard, we have found that the binding of LBP-LPS complexes to this receptor, but not mCD14, is sensitive to a variety of other proteases including chymotrypsin, papain, subtilisin and elastase. The resistance of mCD14 to proteases could be a function of either its highly glycosylated state or its reported location within microdomains of the plasma membrane. 11 Trypsin pretreatment of cells dramatically inhibits the internalization of mCD14 bound LBP-LPS complexes suggesting a general requirement for the trypsin sensitive receptor in the clearance of cell bound LBP-LPS complexes. This non-CD14 mediated binding phenomenon has been detected on a variety of different cell types including human epithelial, fibroblast and myeloid cell lines. Experiments are currently underway to further characterize and identify this novel receptor for LBP-LPS complexes.
